menu search

GTBP / GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKEĀ® platform, today announced that Dr. Jeffrey Miller, MD, GT Bipharma's Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright's Cell Therapy Virtual Conference taking place on February 28, 2023. Company management will also be participating in 1x1 meetings during the event. Read More
Posted: Feb 24 2023, 09:00
Author Name: GlobeNewsWire
Views: 081520

GTBP News  

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

By Zacks Investment Research
June 2, 2023

Here's Why GT Biopharma, Inc. (GTBP) Is a Great 'Buy the Bottom' Stock Now

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an more_horizontal

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

By Zacks Investment Research
May 19, 2023

All You Need to Know About GT Biopharma, Inc. (GTBP) Rating Upgrade to Buy

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d more_horizontal

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

By GlobeNewsWire
February 24, 2023

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on develop more_horizontal

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

By PRNewsWire
January 20, 2022

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

By PRNewsWire
January 20, 2022

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

By PRNewsWire
January 20, 2022

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inno more_horizontal

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

By Seeking Alpha
November 15, 2021

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness more_horizontal

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

By Seeking Alpha
November 15, 2021

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness more_horizontal


Search within

Pages Search Results: